本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Solid Biosciences

4.57
+0.23005.30%
成交量:66.64萬
成交額:300.18萬
市值:3.56億
市盈率:-2.04
高:4.73
開:4.27
低:4.24
收:4.34
52周最高:7.37
52周最低:2.41
股本:7,791.02萬
流通股本:3,761.32萬
量比:0.70
換手率:1.77%
股息:- -
股息率:- -
每股收益(TTM):-2.2440
每股收益(LYR):-3.0550
淨資產收益率:-86.83%
總資產收益率:-43.67%
市淨率:1.63
市盈率(LYR):-1.50

資料載入中...

2023/03/13

重要事件披露

8-K - Current report
2023/02/13

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2023/02/13

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2023/02/10

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2023/02/03

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2023/02/02

SEC問詢函

CORRESP [Cover] - Correspondence
2023/01/09

員工持股計劃

S-8 - Securities to be offered to employees in employee benefit plans
2023/01/09

重要事件披露

8-K - Current report
2022/12/12

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2022/12/06

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2022/12/05

重要事件披露

8-K - Current report
2022/12/05

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2022/12/05

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2022/12/02

員工持股計劃

S-8 - Securities to be offered to employees in employee benefit plans
2022/12/01

重要事件披露

8-K - Current report
2022/11/10

季度報告

10-Q - Quarterly report [Sections 13 or 15(d)]
2022/10/27

重要事件披露

8-K - Current report
2022/10/04

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2022/10/03

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2022/09/30

重要事件披露

8-K - Current report